Equity Profile

CYRX

Cryoport, Inc.

Health CareLife Sciences Tools & Services$790.8M

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Cryoport, Inc. is a healthcare company specializing in life sciences tools and services, particularly focused on temperature-controlled logistics for biopharmaceutical products....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating revenue.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and attract new customers, which is vital for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CYRX Q2-2026 Earnings Preview

Context

Company Snapshot

Cryoport, Inc. is a healthcare company specializing in life sciences tools and services, particularly focused on temperature-controlled logistics for biopharmaceutical products. With a market cap of $1 billion, it plays a crucial role in ensuring the safe transport of sensitive medical products, which is increasingly important as the healthcare industry grows and evolves.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+98.90%

Avg Stock Reaction

+1.25%

Last Quarter Recap

In Q1-2026, Cryoport reported an EPS of -$0.25, missing estimates by 25%. The stock reacted negatively, declining by 1.35% the following day.

Management Promises & Guidance

Focus on improving operational efficiency.
Commitment to expanding customer base in biopharmaceutical logistics.
Plans to enhance technology for temperature-controlled transport.

Expectations

Wall Street Expectations

Overall expectations for Cryoport's upcoming earnings are mixed, with uncertainty surrounding profitability and revenue growth.

Bull Case

If Cryoport can demonstrate strong revenue growth and improved margins, it could signal a turnaround and attract more investors.

Bear Case

Conversely, if the company continues to report losses and fails to show significant revenue growth, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous estimates?

EPS is a critical measure of profitability, and any significant deviation from estimates could impact investor sentiment.

What is the expected revenue growth rate for the next quarter?

Revenue growth is essential for assessing the company's ability to expand and sustain its operations.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Cryoport's potential for revenue growth due to its expanding customer base in biopharmaceutical logistics.

Supporting Evidence

Options are pricing a 25.97% move, indicating high expectations for volatility.

The company's historical performance shows significant surprises in revenue growth, suggesting potential for upside.

Recent operational improvements may not be fully reflected in market sentiment.

Key Risk

If revenue growth exceeds 15%, it could shift the narrative and lead to a reevaluation of the company's prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The debate this quarter centers around whether Cryoport can achieve meaningful revenue growth while managing its costs effectively.

Bull Confirmed If

A revenue growth rate of over 15% would confirm the bull case, indicating strong demand for Cryoport's services.

Bear Confirmed If

If EPS comes in worse than -$0.30, it would confirm the bear case, suggesting ongoing profitability challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±25.97%

Historical Avg

±3.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±26.0% while CYRX has averaged ±3.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

69.4%

Calls (307K)P/C Ratio: 0.00Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cryoport beats expectations, history suggests the stock could rise around 1.99% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious, the stock may see little movement as investors await more clarity from management.

Miss

If the company misses expectations, history suggests a potential drop of around 2.78%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on customer acquisition strategies and any new partnerships.
2Details on operational efficiencies and cost management efforts.
3Insights into the competitive landscape and how Cryoport plans to differentiate itself.
4Any commentary on regulatory changes impacting the logistics of biopharmaceuticals.
5Future guidance on expected revenue growth and profitability targets.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Cryoport, Inc. is a healthcare company specializing in life sciences tools and services, particularly focused on temperature-controlled logistics for biopharmaceutical products....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating revenue.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and attract new customers, which is vital for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CYRX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+98.90%

Avg Stock Reaction

+1.25%

Last Quarter Recap

In Q1-2026, Cryoport reported an EPS of -$0.25, missing estimates by 25%. The stock reacted negatively, declining by 1.35% the following day.

Management Promises & Guidance

Focus on improving operational efficiency.
Commitment to expanding customer base in biopharmaceutical logistics.
Plans to enhance technology for temperature-controlled transport.

Expectations

Wall Street Expectations

Overall expectations for Cryoport's upcoming earnings are mixed, with uncertainty surrounding profitability and revenue growth.

Bull Case

If Cryoport can demonstrate strong revenue growth and improved margins, it could signal a turnaround and attract more investors.

Bear Case

Conversely, if the company continues to report losses and fails to show significant revenue growth, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous estimates?

EPS is a critical measure of profitability, and any significant deviation from estimates could impact investor sentiment.

What is the expected revenue growth rate for the next quarter?

Revenue growth is essential for assessing the company's ability to expand and sustain its operations.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Cryoport's potential for revenue growth due to its expanding customer base in biopharmaceutical logistics.

Supporting Evidence

Options are pricing a 25.97% move, indicating high expectations for volatility.

The company's historical performance shows significant surprises in revenue growth, suggesting potential for upside.

Recent operational improvements may not be fully reflected in market sentiment.

Key Risk

If revenue growth exceeds 15%, it could shift the narrative and lead to a reevaluation of the company's prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The debate this quarter centers around whether Cryoport can achieve meaningful revenue growth while managing its costs effectively.

Bull Confirmed If

A revenue growth rate of over 15% would confirm the bull case, indicating strong demand for Cryoport's services.

Bear Confirmed If

If EPS comes in worse than -$0.30, it would confirm the bear case, suggesting ongoing profitability challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±25.97%

Historical Avg

±3.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±26.0% while CYRX has averaged ±3.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

69.4%

Calls (307K)P/C Ratio: 0.00Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cryoport beats expectations, history suggests the stock could rise around 1.99% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious, the stock may see little movement as investors await more clarity from management.

Miss

If the company misses expectations, history suggests a potential drop of around 2.78%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on customer acquisition strategies and any new partnerships.
2Details on operational efficiencies and cost management efforts.
3Insights into the competitive landscape and how Cryoport plans to differentiate itself.
4Any commentary on regulatory changes impacting the logistics of biopharmaceuticals.
5Future guidance on expected revenue growth and profitability targets.